Monopar Therapeutics Inc. (MNPR) — Financial statements
Income statement, balance sheet, and cash flow for Monopar Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 9,904↑76051.3% | 13↑132.2% | 6↓26.2% | 8↑16.9% | 6 | |
| General & Administrative Expenses | 6,800↑215386.7% | 3↓2.3% | 3↑9.7% | 3↑11.8% | 3 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6,800↑215386.7% | 3↓2.3% | 3↑9.7% | 3↑11.8% | 3 | |
| Other Expenses | -16,688 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 17↑3.4% | 16↑83.0% | 9↓16.2% | 11↑15.4% | 9 | |
| Total Costs & Expenses | 17↑3.4% | 16↑83.0% | 9↓16.2% | 11↑15.4% | 9 | |
| Operating Results | ||||||
| Operating Income | -17↓3.4% | -16↓83.0% | -9↑16.2% | -11↓15.4% | -9 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -17↓3.4% | -16↓83.0% | -9↑16.2% | -11↓15.4% | -9 | |
| EBIT | -17↓3.4% | -16↓83.0% | -9↑16.2% | -11↓15.4% | -9 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑639.4% | 0.40↓5.8% | 0.43↑1920.1% | 0.02↓11.6% | 0.02 | |
| Interest Income | 3↑639.4% | 0.40↓5.8% | 0.43↑1920.1% | 0.02↓11.6% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 3↑419.3% | 0.58↑34.1% | 0.43↑1920.1% | 0.02↓11.6% | 0.02 | |
| Income Before Tax | -14↑12.0% | -16↓85.5% | -8↑20.1% | -11↓15.5% | -9 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -14↑12.0% | -16↓85.5% | -8↑20.1% | -11↓15.5% | -9 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -14↑12.0% | -16↓85.5% | -8↑20.1% | -11↓15.5% | -9 | |
| Bottom-Line Net Income | -14↑12.0% | -16↓85.5% | -8↑20.1% | -11↓15.5% | -9 | |
| EPS (Basic) | -1.85↓36.0% | -1.36↓134.5% | -0.58↑30.1% | -0.83↓13.7% | -0.73 | |
| EPS (Diluted) | -1.85↓36.0% | -1.36↓134.5% | -0.58↑30.1% | -0.83↓13.7% | -0.73 | |
| Weighted Average Shares | 7↓35.2% | 11↓21.1% | 15↑14.1% | 13↑2.0% | 12 | |
| Weighted Average Diluted Shares | 7↓35.5% | 11↓20.9% | 15↑14.1% | 13↑2.0% | 12 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.